News | Pacemakers | May 24, 2018

Permanent Pacing Effective for Older Patients With Syncope and Bifascicular Block

Study finds significant advantages with permanent pacing versus an implantable cardiac monitor for particular patient group

Permanent Pacing Effective for Older Patients With Syncope and Bifascicular Block

May 24, 2018 — Syncope with bifascicular block may be caused by intermittent complete heart block, but competing diagnoses may coexist. A new study tested whether a strategy of empiric permanent pacing (PM) reduces major adverse events more effectively than acting on the results of an implantable cardiac monitor (ICM). Results of the study were presented at Heart Rhythm 2018, the 39th annual scientific sessions of the Heart Rhythm Society (HRS), May 9-12 in Boston.

In a multinational, randomized, pragmatic trial, 56 subjects under 50 years old with bifascicular block, preserved left ventricular function, and less than or equal to one syncope in the preceding year, received PM and 59 received an ICM. The primary outcome measure was a composite of Major Adverse Study-Related Events (MASRE), comprised of death, syncope, symptomatic bradycardia, asymptomatic actionable bradycardia and device complications.

The PM and ICM groups were similar in age, sex, lifetime syncopes, syncope in prior year, duration of symptoms, no prodrome and baseline systolic BP. Forty patients had left bundle branch block and 75 had right bundle branch block and a left hemiblock. Patients were followed for a median 30 months, and 21 exited the study — eight patients died, six withdrew consent after 2 years, four withdrew due to cancer and three due to dementia.

PM effectively prevented the primary outcome with end study MASRE-free survivals in PM (63 percent) and ICM (22 percent) group (p<0.001). The proportions of patients with syncope were similar in PM and ICM groups (27 vs 31 percent, p=0.50, Wilcoxon). Fully 35 out of 59 ICM patients (59 percent) crossed over to PM. There were five pacemaker complications requiring reintervention.

The researchers concluded that permanent pacing compared to ICM is a preferred strategy in elderly patients with few but recent syncopal spells and bifascicular block. This is driven by the high proportion of mildly symptomatic bradycardias detected on ICMs leading to pacemaker insertion.

For more information: www.hrssessions.org

Read more about HRS 2018 late-breaking studies


Related Content

News | Cardiovascular Clinical Studies

May 6, 2026 — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions ...

Home May 06, 2026
Home
News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
Subscribe Now